Plus Therapeutics Expands Agreement with Telix IsoTherapeutics for Rhenium-186 Supply

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company based in Austin, Texas, has announced the renewal of its Master Services Agreement (MSA) with Telix IsoTherapeutics Group Inc., a subsidiary within the Telix Group. This renewed agreement ensures a stable supply of cGMP Rhenium-186 (Re-186), a critical component in Plus Therapeutics' lead radiotherapeutic candidate, Rhenium (186Re) Obisbemeda.

Marc H. Hedrick, M.D., the President and CEO of Plus Therapeutics, highlighted that this agreement with Telix IsoTherapeutics Group complements their existing partnership with SpectronRx. The collaboration with SpectronRx focuses on the final drug manufacturing of Rhenium (186Re) Obisbemeda. Dr. Hedrick emphasized that securing the supply of Re-186 through IsoTherapeutics and utilizing SpectronRx for the final manufacturing steps allows Plus Therapeutics to establish a scalable and comprehensive supply chain. This supply chain is designed to meet the needs of late-stage clinical trials and future commercial production.

The agreement with Telix IsoTherapeutics Group is centered on the production of the key radionuclide intermediate aluminum perrhenate and the final processing of cGMP Re-186. This arrangement facilitates expanded, scalable, and just-in-time manufacturing capabilities to support the overall supply chain.

Rhenium (186Re) Obisbemeda is an innovative injectable radiotherapy specifically designed to deliver targeted high-dose radiation to central nervous system (CNS) tumors. This formulation aims to optimize patient outcomes by providing a safe, effective, and convenient treatment. Rhenium (186Re) Obisbemeda has the potential to minimize off-target risks and enhance patient results compared to currently approved therapies, offering a more focused and potent radiation dose. Rhenium-186 is particularly suitable for CNS therapeutic applications due to its short half-life, beta energy for effective cancerous tissue destruction, and gamma energy for real-time imaging.

Plus Therapeutics is currently evaluating Rhenium (186Re) Obisbemeda for the treatment of recurrent glioblastoma and leptomeningeal metastases in clinical trials named ReSPECT-GBM and ReSPECT-LM. The ReSPECT-GBM trial is supported by an award from the National Cancer Institute (NCI), which is part of the U.S. National Institutes of Health (NIH). The ReSPECT-LM trial is funded by a three-year $17.6M grant from the Cancer Prevention & Research Institute of Texas (CPRIT).

Plus Therapeutics is focused on developing innovative radiotherapeutics for challenging cancers of the central nervous system. The company combines image-guided local beta radiation with targeted drug delivery approaches, advancing a pipeline of product candidates. Their lead programs are in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Plus Therapeutics has established strategic partnerships that facilitate the development, manufacturing, and potential future commercialization of its products. The company operates in key cancer clinical development hubs, including Austin and San Antonio, Texas.

Telix IsoTherapeutics Group, Inc. was founded in 2005 by two entrepreneurial scientists dedicated to advancing radiopharmaceutical technology. The company has received over 100 patents for its developments in chemistry and radiopharmaceutical formulations. In April 2024, IsoTherapeutics was acquired by Telix Pharmaceuticals Limited (Telix) and now operates within the Telix Manufacturing Solutions business unit. This unit comprises a global network of facilities, infrastructure, and technologies capable of supplying patient doses worldwide, fulfilling the promise of nuclear medicine.